Platelet inhibition with cangrelor in patients undergoing PCI

New England Journal of Medicine

Volumn 361, Issue 24, 2009, Pages 2318-2329

  Harrington, Robert A ^a   Stone, Gregg W ^b   McNulty, Steven ^a   White, Harvey D ^c   Lincoff, A Michael ^d   Gibson, C Michael ^e   Pollack Jr , Charles V ^g   Montalescot, Gilles ^h   Mahaffey, Kenneth W ^a   Kleiman, Neal S ⁱ   Goodman, Shaun G ^k   Amine, Maged ^j   Angiolillo, Dominick J ^l   Becker, Richard C ^a   Chew, Derek P ^m   French, William J ⁿ   Leisch, Franz ^o   Parikh, Keyur H ^p   Skerjanec, Simona ^q   Bhatt, Deepak L ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d LERNER RESEARCH INSTITUTE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g PENNSYLVANIA HOSPITAL   (United States)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ HOUSTON METHODIST HOSPITAL   (United States)

^j Northwest Heart Center   (United States)

^k ST MICHAEL'S HOSPITAL   (Canada)

^l UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^m FLINDERS UNIVERSITY   (Australia)

ⁿ HARBOR UCLA MEDICAL CENTER   (United States)

^o KEPLER UNIVERSITY HOSPITAL   (Austria)

^p The Heart Care Clinic   (India)

^q MEDICINES COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; EMERGENCY HEALTH SERVICE; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 71849087338     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0908628     Document Type: Article

References (35)

1. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines CL, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl: 576S-599S. (Pubitemid 39302605)
2. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007;116:1952-1965
3. Maisel WH. Unanswered questions - drug-eluting stents and the risk of late stent thrombosis. N Engl J Med 2007;356: 981-984 (Pubitemid 46376797)
4. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68 (Pubitemid 9229695)
5. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused update of the ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee. Circulation 2008;117: 261-295
6. Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. Eur Heart J 2005;26:804-847
7. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396
8. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-317
9. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362
10. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006;3:387-395
11. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111:3366-3373
12. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-1851 (Pubitemid 350007959)
13. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057
14. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015 (Pubitemid 350106708)
15. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925-934 (Pubitemid 30804486)
16. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002;13:407-413 (Pubitemid 35346941)
17. Behan MW, Fox SC, Heptinstall S, Storey RF. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 2005;16:73-80. (Pubitemid 40516671)
18. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006; 151(3):689.e1-689.e10.
19. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361. DOI: 10.1056/NEJMoa0908629.
20. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-2653
21. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351 (Pubitemid 46685903)
22. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329: 673-682 [Erratum, N Engl J Med 1994;331: 277.]
23. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-154 (Pubitemid 17093202)
24. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203-2216 (Pubitemid 44791162)
25. International Conference on Harmonization (ICH) guidance documents. Silver Spring, MD: Food and Drug Administration. (Accessed November 12, 2009, at http:// www.fda.gov/RegulatoryInformation/ Guidances/ucm122049.htm.)
26. Mahaffey KW, Roe MT, Dyke CK, et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 2002;143: 242-248
27. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-2044
28. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis- II. Lancet 1997;349:1422-1428
29. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 2009;119: 597-605.
30. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533 (Pubitemid 32772726)
31. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189 (Pubitemid 40397259)
32. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
33. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621 (Pubitemid 41552416)
34. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-1363
35. Double doses of clopidogrel better than standard doses for heart patients undergoing angioplasty, an international study finds. Press release from the European Society of Cardiology ESC Congress 2009, Barcelona, August 30, 2009. (Accessed November 12, 2009, at http://www. escardio.org/about/press/press- releases/ esc09-barcelona/Pages/esc-2009-Mehta- Current%20Oasis%207.aspx.)